Zurich, 10. August 2023 – Canna Capital Group, a swiss holding company investing in CBD-centric enterprises and projects, is thrilled to announce its strategic partnership with Switzerland-based Medropharm AG. As a licensed and well-established manufacturer and trader of medical cannabis products, Medropharm AG’s alliance with Canna Capital Group underscores both entities’ commitment to enhancing their global footprint.
This collaboration seeks to streamline the vision and operational strategies of both companies, leveraging their combined strengths, market knowledge, and innovative approaches. The objective is to tap into new markets, capitalize on budding opportunities, and cater to an ever-increasing consumer demand for top-tier CBD and medical cannabis products.
“The of our forces with Medropharm AG is more than just a business decision. It represents our shared aspiration to lead the global CBD and medical cannabis market with unparalleled quality, ethics, and innovation,” said Ulas Yavuz, CEO of Canna Capital Group. ”
The immediate focus of this partnership will be to identify and harness synergies between the two firms, ensuring streamlined operations, increased efficiencies, and maximized shareholder value. Both Canna Capital Group and Medropharm AG anticipate a long-term, strong relationship that will be instrumental in setting industry benchmarks and establishing a dominant presence.
For more details, or to arrange an interview, please contact:
About Canna Capital Group: Canna Capital Group is a swiss holding company with a focus on global investments in CBD-related ventures and projects. With an eye for innovation and quality, the company has fostered a rich portfolio that spans multiple sectors within the growing CBD and cannabis market.
About Medropharm AG: Medropharm AG is a Swiss-based, licensed manufacturer and trader specializing in medical cannabis products. With its rigorous commitment to quality, safety, and customer satisfaction, Medropharm AG has established a strong position for itself in the medical cannabis landscape in Switzerland.